Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
AstraZeneca
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Austrian Breast & Colorectal Cancer Study Group
ClinicalTrials.gov Identifier:
NCT00295646
First received: February 23, 2006
Last updated: October 17, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2015
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
No publications provided by Austrian Breast & Colorectal Cancer Study Group

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):